Oblato acquires all rights to glioblastoma drug from OMRF
October 29, 2018 11:21 ET
|
Oklahoma Medical Research Foundation
OKLAHOMA CITY, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Oblato, Inc., has acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of...